Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug...

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Advanced prostate cancer (PCa) treatments face limitations, particularly resistance to enzalutamide.
• Epichlorohydrin scaffolds (EPI) show promise but have suboptimal pharmacokinetics.
• Current therapies struggle with efficacy in later stages of PCa.

Purpose of the Study:

• To synthesize and characterize novel hybrid molecules combining enzalutamide and EPI-001.
• To evaluate the efficacy and mechanism of action of these new compounds against PCa cells.
• To develop a new class of androgen receptor (AR) inhibitors with improved therapeutic potential.

Main Methods:

• Covalent linkage of enzalutamide and EPI-001 using triazole-based linkers.
• Synthesis and biological characterization of the novel hybrid compounds.
• Assessment of cell killing potency in C4-2b PCa cells and investigation of AR-mediated pathways.

Main Results:

• The novel hybrid compounds demonstrated an 18 to 53-fold improvement in cell killing potency compared to enzalutamide and EPI-001.
• The most effective compounds exhibited toxicity exclusively through AR-mediated pathways.
• Successful combination of two distinct drug moieties into a single molecule.

Conclusions:

• This study introduces the first class of hybrid AR inhibitors merging enzalutamide and EPI-001.
• These novel compounds offer enhanced potency and a promising therapeutic strategy for advanced prostate cancer.
• The findings pave the way for next-generation AR-targeted therapies in oncology.